Shots:
- Enodia Therapeutics has entered into a research collaboration & license agreement with Pfizer to discover & develop Sec61-targeting small-molecule therapeutics leveraging Enodia’s platform
- As per the deal, Enodia will screen, optimize, & develop Sec61 inhibitor candidates against multiple collaboration targets, while Pfizer will assume responsibility for clinical development, manufacturing, regulatory affairs, & commercialization after the collaboration term
- Enodia will receive an upfront payment and research, development & sales milestone payments as well as net sales-based tiered royalties, bringing the total potential deal value to more than $500M
Ref: Businesswire | Image: Enodia & Pfizer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
